<DOC>
	<DOCNO>NCT00003630</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness arsenic trioxide treat patient advance solid tumor .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) arsenic trioxide adult pediatric patient advance solid tumor . II . Determine pattern clinical adverse experience arsenic trioxide patient population . III . Evaluate evidence clinical responsiveness treatment regimen . OUTLINE : This dose escalation , open label study . Patients stratified age ( pediatric v adult ) . Patients receive arsenic trioxide IV 1-2 hour daily 3 consecutive day weekly 5 week . Patients stable respond disease receive additional course therapy every 8 week 1 year absence disease progression unacceptable toxicity . Patients receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 patient 6 experience dose limit toxicity . Patients follow least 1 month treatment . PROJECTED ACCRUAL : Approximately 48 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor Relapsed resistant least 1 course standard anticancer therapy AND/OR Lack standard therapy know beneficial underlying disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 2.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 month follow study No active serious infection control antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>